DS-2248 / Daiichi Sankyo - LARVOL DELTA

Effects of a combined treatment regimen consisting of Hsp90 inhibitor DS-2248 and radiation in vitro and in a tumor mouse model. (PubMed, Transl Cancer Res) - "The combined effects of DS-2248 and radiation were additive at low drug and radiation doses, but may have been supra-additive at higher doses. Inhibition of slow repair of DNA double strand breaks (i.e., homologous recombination) was considered to contribute to this combined effect."

Journal • Preclinical • Oncology • Squamous Cell Carcinoma • Transplantation • HSP90AA1

A Study of DS-2248, in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=60; Terminated; Sponsor: Daiichi Sankyo Inc.; N=88 ➔ 60; Recruiting ➔ Terminated; Trial primary completion date: Aug 2014 ➔ Mar 2014

Clinical • Enrollment change • Trial primary completion date • Trial termination